|
CD74 expression based on
|
Statistics: Unpaired two sample T-test was employed to evaluate levels of significance in expression level between any two sample groups
| Comparison | Statistical significance |
| Normal-vs-Primary | 7.895600E-02 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.156400E-02 |
| Normal-vs-Stage2 |
1.052960E-01 |
| Normal-vs-Stage3 |
5.238300E-02 |
| Normal-vs-Stage4 |
2.963600E-02 |
| Stage1-vs-Stage2 |
1.1887999995519E-07 |
| Stage1-vs-Stage3 |
9.442600E-01 |
| Stage1-vs-Stage4 |
5.553600E-01 |
| Stage2-vs-Stage3 |
2.03359999995101E-06 |
| Stage2-vs-Stage4 |
2.18669999999532E-05 |
| Stage3-vs-Stage4 |
4.850200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.851700E-02 |
| Normal-vs-AfricanAmerican |
7.134400E-01 |
| Normal-vs-Asian |
9.580100E-02 |
| Caucasian-vs-AfricanAmerican |
2.449200E-01 |
| Caucasian-vs-Asian |
9.500800E-01 |
| AfricanAmerican-vs-Asian |
3.041800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.121200E-01 |
| Normal-vs-Female |
6.722500E-02 |
| Male-vs-Female |
3.503600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
8.934000E-02 |
| Normal-vs-Age(41-60Yrs) |
8.693600E-02 |
| Normal-vs-Age(61-80Yrs) |
4.835200E-01 |
| Normal-vs-Age(81-100Yrs) |
2.573400E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.703800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.569190E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.565200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.161400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.468800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.422600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.496300E-03 |
| Classical-VS-Follicular |
4.71778172084214E-12 |
| Classical-VS-Other |
4.542200E-03 |
| Classical-VS-Normal |
4.245500E-02 |
| Tall-VS-Follicular |
2.88724599784018E-12 |
| Tall-VS-Other |
3.73260000000597E-05 |
| Tall-VS-Normal |
3.191800E-04 |
| Follicular-VS-Other |
5.066800E-01 |
| Follicular-VS-Normal |
3.323900E-02 |
| Other-VS-Normal |
3.448200E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.590600E-01 |
| Normal-vs-N1 |
8.269600E-02 |
| N0-vs-N1 |
1.628980E-01 |
|
|
